pyrroles has been researched along with olaparib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Ge, Y; Niu, X; Tan, W; Wang, G; Wang, H; Zhao, J; Zhao, L | 1 |
| Blucher, A; Chelariu-Raicu, A; Chen, TH; Coleman, RL; Creason, A; Fang, Y; Fellman, B; Feng, N; Frumovitz, M; Jazaeri, A; Kabil, N; Kim, TB; Labrie, M; Lee, S; Litton, JK; Liu, J; Lu, KH; Ma, X; Marszalek, JR; Meyer, LA; Mills, GB; Murthy, R; Schmeler, KM; Soliman, PT; Sood, AK; Sun, CC; Vellano, CP; Westin, SN; Yuan, Y | 1 |
1 trial(s) available for pyrroles and olaparib
| Article | Year |
|---|---|
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Pyrimidines; Pyrroles; Triple Negative Breast Neoplasms | 2021 |
1 other study(ies) available for pyrroles and olaparib
| Article | Year |
|---|---|
Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Indoles; Mice, Inbred BALB C; Mice, Nude; Necrosis; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Time Factors; Xenograft Model Antitumor Assays | 2014 |